177 related articles for article (PubMed ID: 33304100)
1. Silencing of MEF2D by siRNA Loaded Selenium Nanoparticles for Ovarian Cancer Therapy.
Wang C; Xia Y; Huo S; Shou D; Mei Q; Tang W; Li Y; Liu H; Zhou Y; Zhu B
Int J Nanomedicine; 2020; 15():9759-9770. PubMed ID: 33304100
[TBL] [Abstract][Full Text] [Related]
2. Functionalized selenium nanoparticles for targeted siRNA delivery silence Derlin1 and promote antitumor efficacy against cervical cancer.
Xia Y; Tang G; Wang C; Zhong J; Chen Y; Hua L; Li Y; Liu H; Zhu B
Drug Deliv; 2020 Dec; 27(1):15-25. PubMed ID: 31830840
[TBL] [Abstract][Full Text] [Related]
3. Silencing KLK12 expression via RGDfC-decorated selenium nanoparticles for the treatment of colorectal cancer in vitro and in vivo.
Xia Y; Tang G; Guo M; Xu T; Chen H; Lin Z; Li Y; Chen Y; Zhu B; Liu H; Cao J
Mater Sci Eng C Mater Biol Appl; 2020 May; 110():110594. PubMed ID: 32204058
[TBL] [Abstract][Full Text] [Related]
4. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy.
Xia Y; Xu T; Wang C; Li Y; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():143-159. PubMed ID: 29317822
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional selenium nanoparticles as carriers of HSP70 siRNA to induce apoptosis of HepG2 cells.
Li Y; Lin Z; Zhao M; Xu T; Wang C; Xia H; Wang H; Zhu B
Int J Nanomedicine; 2016; 11():3065-76. PubMed ID: 27462151
[TBL] [Abstract][Full Text] [Related]
6. Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy.
Xia Y; Chen Y; Hua L; Zhao M; Xu T; Wang C; Li Y; Zhu B
Int J Nanomedicine; 2018; 13():6929-6939. PubMed ID: 30464451
[TBL] [Abstract][Full Text] [Related]
7. siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy.
Xia Y; Guo M; Xu T; Li Y; Wang C; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():1539-1552. PubMed ID: 29588583
[TBL] [Abstract][Full Text] [Related]
8. Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma.
Xia Y; Zhong J; Zhao M; Tang Y; Han N; Hua L; Xu T; Wang C; Zhu B
Drug Deliv; 2019 Dec; 26(1):1-11. PubMed ID: 31928356
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy.
Xia Y; Xiao M; Zhao M; Xu T; Guo M; Wang C; Li Y; Zhu B; Liu H
Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110100. PubMed ID: 31753388
[TBL] [Abstract][Full Text] [Related]
10. Engineering siRNA-loaded and RGDfC-targeted selenium nanoparticles for highly efficient silencing of DCBLD2 gene for colorectal cancer treatment.
Huang H; Chen H; Shou D; Quan Y; Cheng J; Chen H; Ning G; Li Y; Xia Y; Zhou Y
Discov Nano; 2023 Jul; 18(1):94. PubMed ID: 37477789
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeted delivery of siRNA to silence Sox2 gene expression enhances therapeutic response in hepatocellular carcinoma.
Xia Y; Tang G; Chen Y; Wang C; Guo M; Xu T; Zhao M; Zhou Y
Bioact Mater; 2021 May; 6(5):1330-1340. PubMed ID: 33210026
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy.
Zou J; Su S; Chen Z; Liang F; Zeng Y; Cen W; Zhang X; Xia Y; Huang D
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3456-3464. PubMed ID: 31469318
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of siRNA using RGDfC-conjugated functionalized selenium nanoparticles for anticancer therapy.
Xia Y; Lin Z; Li Y; Zhao M; Wang C; Guo M; Zhang B; Zhu B
J Mater Chem B; 2017 Sep; 5(33):6941-6952. PubMed ID: 32264343
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance.
Zheng W; Cao C; Liu Y; Yu Q; Zheng C; Sun D; Ren X; Liu J
Acta Biomater; 2015 Jan; 11():368-80. PubMed ID: 25204523
[TBL] [Abstract][Full Text] [Related]
15. GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways.
Pi J; Jiang J; Cai H; Yang F; Jin H; Yang P; Cai J; Chen ZW
Drug Deliv; 2017 Nov; 24(1):1549-1564. PubMed ID: 29019267
[TBL] [Abstract][Full Text] [Related]
16. The use of pH-sensitive functional selenium nanoparticles shows enhanced in vivo VEGF-siRNA silencing and fluorescence imaging.
Yu Q; Liu Y; Cao C; Le F; Qin X; Sun D; Liu J
Nanoscale; 2014 Aug; 6(15):9279-92. PubMed ID: 24986368
[TBL] [Abstract][Full Text] [Related]
17. Application of Selenium Nanoparticles in Localized Drug Targeting for Cancer Therapy.
Nath D; Kaur L; Sohal HS; Malhi DS; Garg S; Thakur D
Anticancer Agents Med Chem; 2022 Aug; 22(15):2715-2725. PubMed ID: 35168523
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional selenium nanoparticles: Chiral selectivity of delivering MDR-siRNA for reversal of multidrug resistance and real-time biofluorescence imaging.
Chen Q; Yu Q; Liu Y; Bhavsar D; Yang L; Ren X; Sun D; Zheng W; Liu J; Chen LM
Nanomedicine; 2015 Oct; 11(7):1773-84. PubMed ID: 25959925
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of HES5-siRNA with novel polypeptide-modified nanoparticles for hepatocellular carcinoma therapy.
Xia Y; Wang C; Xu T; Li Y; Guo M; Lin Z; Zhao M; Zhu B
RSC Adv; 2018 Jan; 8(4):1917-1926. PubMed ID: 35542585
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β-tubulin in drug-resistant breast cancers.
Zheng W; Yin T; Chen Q; Qin X; Huang X; Zhao S; Xu T; Chen L; Liu J
Acta Biomater; 2016 Feb; 31():197-210. PubMed ID: 26612416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
